Buy now for a catalyst-driven rebound setup: price is sitting near key support (S1 ~5.18 / S2 ~5.00) while sentiment/catalysts are improving.
The risk/reward favors upside if it reclaims the pivot (~5.48) and pushes toward resistance (5.78–5.96), aligning with Street targets ($6–$8).
Despite bearish momentum (MACD), the short-term oversold condition plus bullish options skew and recent FDA clearance make KRMD a good buy right now for an impatient trader looking for near-term upside.
Technical Analysis
Trend/Momentum: MACD histogram is negative (-0.0499) and expanding lower, signaling downside momentum still active.
RSI: RSI_6 at ~27.45 indicates an oversold/washed-out short-term condition (often consistent with bounce setups).
Moving averages: Converging MAs suggest compression/transition rather than a clean uptrend; price action needs a reclaim of the pivot to confirm strength.
Levels to watch: Pivot 5.48 is the key inflection; support at 5.18 then 5.00; upside resistance at 5.78 and 5.96.
Pattern-based expectation: Similar-pattern model suggests modest next-day upside (+0.73%), potential near-week softness (-1.61%), and a positive 1-month bias (+4.59%).
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning skew is strongly bullish: very low put/call open interest ratio (0.04) and low put/call volume ratio (0.33) imply more call interest than puts.
Activity note: absolute options volume is very small (4 contracts total), so sentiment reads are directionally useful but not high-confidence.
Volatility: 30D IV is extremely elevated (273%) versus historical vol (54%), consistent with event-driven pricing; IV has also cooled vs the 5–10D average, suggesting the biggest catalyst premium may have already started to come out.
Today’s volume vs 30D average is high (26.67x), but from a low base—still indicates fresh attention.
Technical Summary
Sell
7
Buy
6
Positive Catalysts
suggest improving institutional narrative.
Neutral/Negative Catalysts
Technical pressure remains: bearish/expanding negative MACD indicates the down-move may not be fully finished.
Profitability still not in place: net loss expanded YoY and gross margin declined, which can cap near-term multiple expansion.
No notable supportive flow signals: hedge funds and insiders are reported as neutral; no congress trading data to reinforce a directional bet.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: $10.40M, up +27.17% YoY (clear top-line growth acceleration).
Net income: -$0.78M, down -50.79% YoY (loss widened vs prior year quarter).
EPS: -$0.02, down -33.33% YoY.
Gross margin: 58.26%, down -3.88% YoY (margin compression offsets some of the revenue strength).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent Street trend is strengthening: all cited notes maintain Buy ratings and raised targets.
2025-12-22: Lake Street raised PT to $8 from $6 (Buy), highlighting 510K/catalyst pathway and 2026 growth acceleration.
2025-12-17: Canaccord raised PT to $6 from $5 (Buy), updating longer-range estimates.
2025-11-13: Craig-Hallum raised PT to $6.25 from $6 (Buy) after a strong quarter and raised guidance.
Wall St cons: ongoing losses and some gross margin erosion keep execution risk elevated.
Wall Street analysts forecast KRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRMD is 6.25 USD with a low forecast of 4 USD and a high forecast of 8 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast KRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRMD is 6.25 USD with a low forecast of 4 USD and a high forecast of 8 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.870
Low
4
Averages
6.25
High
8
Current: 4.870
Low
4
Averages
6.25
High
8
Lake Street
Buy
upgrade
$6 -> $8
AI Analysis
2025-12-22
Reason
Lake Street
Price Target
$6 -> $8
AI Analysis
2025-12-22
upgrade
Buy
Reason
Lake Street raised the firm's price target on Koru Medical to $8 from $6 and keeps a Buy rating on the shares. The firm, which thinks a 510K submission for the oncology indication prior to year-end is "a meaningful catalyst, expects 2026 to be another year of growth acceleration and improving leverage, supporting revenue upside and multiple expansion, the analyst tells investors.
Canaccord
Buy
maintain
$5 -> $6
2025-12-17
Reason
Canaccord
Price Target
$5 -> $6
2025-12-17
maintain
Buy
Reason
Canaccord raised the firm's price target on Koru Medical to $6 from $5 and keeps a Buy rating on the shares. The firm updated its model to reflect their new 2027 estimates.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KRMD
